Market atlas / Sirtuin activators (STAC) / Resveratrol

Resveratrol (sirtuin activator, STAC)

traditional-to-validatedsmall-moleculesirtuin-activationpolyphenol● sirt1

Stage by geography

signalpreclinfirst-in-humanRCTapprovedreal-worldconsumerUSUKCNSGIL+3 stages

MarketsUS United States FDAUK United Kingdom MHRA / NICECN China NMPAIN India CDSCOJP Japan PMDACH Switzerland SwissmedicSG Singapore HSAIL Israel Ministry of HealthKR South Korea MFDS

What each market approved it for

Market	Stage	Since	Indication / class / form
US	consumer	not dated	not published
UK	first-in-human	2004-09-01	not published
CN	RCT	2021-05-01	not published
SG	RCT	not dated	not published
IL	signal	not dated	not published

Biomarker trends

no biomarker readings yet

Studies

The studies on Resveratrol, what they found, in whom and how strongly, are on its evidence page, each linked to its source.

What the trials measure

Registered primary outcomes this development's trials are powered on, commonest first (ClinicalTrials.gov). What is measured, across markets.

Registered primary endpoint	Markets measuring it
Bone biomarker	US
Change in endothelial function	US
Change in Drusen Volume from Baseline	US
Geographic Atrophy (GA) Growth Rate	US
Progression to Moderate Vision Loss	US
Adverse Events	US
6-Minute Walk Distance, Meters	US
Change in serum estradiol levels in postmenopausal women with high BMI	US
Change in Sirt1 concentrations	US
Change in vascular health	US

Connections

Trajectory

2004

MarketUK: first-in-human (early clinical (phase 1))

NCT00098969 · machine-extracted

2008

Relatedshares a mechanism with Pterostilbene

NCT01354977 · machine-extracted

2008

ProfileResveratrol (sirtuin activator, STAC)

NCT01354977 · machine-extracted

2008

MarketUS: rct (clinical trials (highest phase 2))

NCT01354977 · machine-extracted

2021

MarketCN: rct (clinical trials (highest phase 3))

NCT04886297 · machine-extracted

2026

MarketUS: consumer (US dietary supplement (DSHEA), not FDA-approved as a drug)

DSLD:228981 · machine-extracted

2026

MarketIL: signal (clinical trials (highest phase ?))

NCT01747252 · machine-extracted

2026

MarketSG: rct (clinical trials (highest phase 2))

NCT02247596 · machine-extracted

Get into the weeds: raw observations + provenance

resv_uk  2026-06-29  kind=geography_stage  verify=M
   Resveratrol: UK early-phase trials [NCT00098969]
   source NCT00098969  https://clinicaltrials.gov/study/NCT00098969

resv_edge_pter  2026-06-29  kind=edge  verify=M
   both stilbene sirtuin-activator polyphenols
   source NCT01354977  https://clinicaltrials.gov/study/NCT01354977

resv_facets  2026-06-29  kind=facets  verify=M
   Resveratrol facets
   source NCT01354977  https://clinicaltrials.gov/study/NCT01354977

resv_us_trial  2026-06-29  kind=geography_stage  verify=M
   Resveratrol: US phase 2 trials [NCT01354977]
   source NCT01354977  https://clinicaltrials.gov/study/NCT01354977

resv_cn  2026-06-29  kind=geography_stage  verify=M
   Resveratrol: a registered phase 3 trial in China [NCT04886297]
   source NCT04886297  https://clinicaltrials.gov/study/NCT04886297

resv_us_consumer  2026-06-29  kind=geography_stage  verify=M
   Resveratrol sold as a US dietary supplement
   source DSLD:228981  https://dsld.od.nih.gov/label/228981

ctsearch__IL__dev_resveratrol  2026-07-10  kind=geography_stage  verify=M
   resveratrol: 1 registered trial(s) in IL, highest phase ? [NCT01747252]
   source NCT01747252  https://clinicaltrials.gov/study/NCT01747252

ctsearch__SG__dev_resveratrol  2026-07-10  kind=geography_stage  verify=M
   resveratrol: 2 registered trial(s) in SG, highest phase 2 [NCT02247596]
   source NCT02247596  https://clinicaltrials.gov/study/NCT02247596